Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;76(6):1291-1305.
doi: 10.1016/j.jhep.2021.11.004.

Haemostatic alterations and management of haemostasis in patients with cirrhosis

Affiliations
Free article
Review

Haemostatic alterations and management of haemostasis in patients with cirrhosis

Ton Lisman et al. J Hepatol. 2022 Jun.
Free article

Abstract

Patients with cirrhosis frequently acquire complex changes in their haemostatic system including a decreased platelet count and decreased levels of various haemostatic proteins. Although historically patients with cirrhosis were thought to have a haemostasis-related bleeding tendency, it is now widely accepted that the haemostatic system of patients with cirrhosis remains in balance as a result of simultaneous changes in pro- and anti-haemostatic systems. The concept of rebalanced haemostasis has led to changes in clinical management, although firm evidence from well-designed clinical studies is largely lacking. For example, many invasive procedures in patients with cirrhosis and a prolonged prothrombin time are now performed without prophylaxis with fresh frozen plasma. Conversely, clinicians have become more aware of the need for anti-thrombotic therapy, even in those patients with abnormal routine coagulation tests. This paper will outline recent advances in pathogenesis, prevention and treatment of both bleeding and thrombotic complications in patients with cirrhosis. Among other topics, we will discuss the haemostatic status of acutely ill patients with cirrhosis, the various causes of bleeding in patients with cirrhosis, and how best to prevent or treat bleeding. In addition, we will discuss the hypercoagulable features of patients with cirrhosis, new insights into the pathogenesis of portal vein thrombosis, and how best to prevent or treat thromboses.

Keywords: bleeding; coagulation; fresh frozen plasma; liver disease; platelets; portal vein thrombosis; thrombosis; variceal bleeding.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest TL has no conflicts of interest to report. NMI reports education grant support from Dova. SHC reports research sponsored trials (NASH, PBC, PSC) from Gilead, Madrigal, BMS, GenFit, Zydus, Galectin, Akero, Galmed, and Inventiva; Royalty for device from Avanos; Honoraria for Lectures from Houston Methodist, University Washington, Thomas Jefferson University; Grant support for Coagulation in Liver Disease meeting from Shionogi and Dova. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

Similar articles

Cited by

LinkOut - more resources